{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:48:25Z","timestamp":1787507305027,"version":"build-2736575974"},"reference-count":38,"publisher":"American Society for Microbiology","issue":"10","license":[{"start":{"date-parts":[[2017,9,22]],"date-time":"2017-09-22T00:00:00Z","timestamp":1506038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NIH R01 HD070886"],"award-info":[{"award-number":["NIH R01 HD070886"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 GM068968"],"award-info":[{"award-number":["R01 GM068968"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"DH | National Institute for Health Research","doi-asserted-by":"publisher","award":["CS\/08\/08"],"award-info":[{"award-number":["CS\/08\/08"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2017,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    The aim of this study was to develop a population pharmacokinetic (PK) model for teicoplanin across childhood age ranges to be used as Bayesian prior information in the software constructed for individualized therapy. We developed a nonparametric population model fitted to PK data from neonates, infants, and older children. We then implemented this model in the BestDose multiple-model Bayesian adaptive control algorithm to show its clinical utility. It was used to predict the dosages required to achieve optimal teicoplanin predose targets (15 mg\/liter) from day 3 of therapy. We performed individual simulations for an infant and a child from the original population, who provided early first dosing interval concentration-time data. An allometric model that used weight as a measure of size and that also incorporated renal function using the estimated glomerular filtration rate (eGFR), or the ratio of postnatal age (PNA) to serum creatinine concentration (SCr) for infants &lt;3 months old, best described the data. The median population PK parameters were as follows: elimination rate constant (Ke) = 0.03 \u00b7 (wt\/70)\n                    <jats:sup>\u22120.25<\/jats:sup>\n                    \u00b7 Renal (h\n                    <jats:sup>\u22121<\/jats:sup>\n                    );\n                    <jats:italic>V<\/jats:italic>\n                    = 19.5 \u00b7 (wt\/70) (liters); Renal = eGFR\n                    <jats:sup>0.07<\/jats:sup>\n                    (ml\/min\/1.73 m\n                    <jats:sup>2<\/jats:sup>\n                    ), or Renal = PNA\/SCr (\u03bcmol\/liter). Increased teicoplanin dosages and alternative administration techniques (extended infusions and fractionated multiple dosing) were required in order to achieve the targets safely by day 3 in simulated cases. The software was able to predict individual measured concentrations and the dosages and administration techniques required to achieve the desired target concentrations early in therapy. Prospective evaluation is now needed in order to ensure that this individualized teicoplanin therapy approach is applicable in the clinical setting. (This study has been registered in the European Union Clinical Trials Register under EudraCT no. 2012-005738-12.)\n                  <\/jats:p>","DOI":"10.1128\/aac.00707-17","type":"journal-article","created":{"date-parts":[[2017,7,31]],"date-time":"2017-07-31T20:35:13Z","timestamp":1501533313000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":19,"title":["Tools for the Individualized Therapy of Teicoplanin for Neonates and Children"],"prefix":"10.1128","volume":"61","author":[{"given":"V.","family":"Ramos-Mart\u00edn","sequence":"first","affiliation":[{"name":"Antimicrobial Pharmacodynamics and Therapeutics, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom"},{"name":"Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. N.","family":"Neely","sequence":"additional","affiliation":[{"name":"Laboratory of Applied Pharmacokinetics and Bioinformatics, The Saban Research Institute and Division of Pediatric Infectious Diseases, Children's Hospital Los Angeles, University of Southern California, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Padmore","sequence":"additional","affiliation":[{"name":"Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Peak","sequence":"additional","affiliation":[{"name":"Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. W.","family":"Beresford","sequence":"additional","affiliation":[{"name":"Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom"},{"name":"Department of Women's and Children's Health, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. A.","family":"Turner","sequence":"additional","affiliation":[{"name":"Liverpool Women's NHS Foundation Trust, Liverpool, United Kingdom"},{"name":"Department of Women's and Children's Health, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Paulus","sequence":"additional","affiliation":[{"name":"Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"L\u00f3pez-Herce","sequence":"additional","affiliation":[{"name":"Servicio de Cuidados Intensivos Pedi\u00e1tricos, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria del Hospital Gregorio Mara\u00f1\u00f3n, Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. W.","family":"Hope","sequence":"additional","affiliation":[{"name":"Antimicrobial Pharmacodynamics and Therapeutics, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03685-14"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw295"},{"key":"e_1_3_2_4_2","first-page":"289","volume-title":"British National Formulary for Children","author":"British Medical Association, Royal Pharmaceutical Society, Royal College of Paediatrics and Child Health, Neonatal and Paediatric Pharmacists Group","year":"2015","unstructured":"British Medical Association, Royal Pharmaceutical Society, Royal College of Paediatrics and Child Health, Neonatal and Paediatric Pharmacists Group. 2015\u20132016. Antibacterial drugs\u2014teicoplanin, p 289\u2013290. InBritish National Formulary for Children. BMJ Group, London, United Kingdom."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200443060-00004"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-199606000-00005"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/44.3.407"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12710"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2012.05.025"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2015.05.019"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq266"},{"key":"e_1_3_2_12_2","volume-title":"Targocid 200 mg. Summary of product characteristics","author":"The Electronic Medicines Compendium","year":"2014","unstructured":"The Electronic Medicines Compendium. 2014. Targocid 200 mg. Summary of product characteristics. Datapharm Communications Limited, Leatherhead, Surrey, United Kingdom. https:\/\/www.medicines.org.uk\/emc\/medicine\/27319."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10156-011-0325-z"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/45.6.835"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10156-010-0105-1"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10156-011-0272-8"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro862"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2013.08.018"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000001456"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2014.07.005"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt176"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr531"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2009.12.018"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e318161a38c"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.23574"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2014.07.006"},{"key":"e_1_3_2_27_2","volume-title":"4th Int Congr Ther Drug Monit Toxicol","author":"Yamada Y","year":"2015","unstructured":"Yamada Y SchaiquevichP NeelyM. 2015. AUC-targeted vancomycin dosing in term and pre-term neonates, abstr. 347, poster 048. 4th Int Congr Ther Drug Monit Toxicol, Rotterdam, Netherlands, 11 to 15 October 2015."},{"key":"e_1_3_2_28_2","first-page":"1","article-title":"Schwartz creatinine clearance is not the best description of infant gentamicin elimination","volume":"4","author":"Neely M","year":"2015","unstructured":"Neely M FloydR. 2015. Schwartz creatinine clearance is not the best description of infant gentamicin elimination. Clin Pharmacol Drug Dev4(S1):1\u201360.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(84)80479-5"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e31825c4ba6"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.48.113006.094708"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13160"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.284.5420.1677"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.2003.tb02576.x"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(86)80245-1"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02025-12"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00032-15"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00852829"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx289"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00707-17","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00707-17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T15:46:56Z","timestamp":1645458416000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00707-17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["10.1128\/AAC.00707-17"],"URL":"https:\/\/doi.org\/10.1128\/aac.00707-17","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"2017-04-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-07-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-09-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00707-17"}}